6 Aptamers for Targeted Therapy
171
124. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KA, Bird PA, Lee CS, Shnier R, Portek IJ
(2006) Synovial membrane cytokine expression is predictive of joint damage progression in
rheumatoid arthritis - A two-year prospective study (the DAMAGE study cohort). Arthritis
Rheum 54(4):1122–1131
125. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, Kaplin AI, Nath A,
Kerr DA, Calabresi PA (2008) Interleukin-17 in transverse myelitis and multiple sclerosis. J
Neuroimmunol 196(1–2):124–132
126. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham
C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang HY, Targan S, Datta LW, Kistner
EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH (2006)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
Science 314(5804):1461–1463
127. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM (2009) Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58(6):1302–1311
128. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J
(2001) IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to
produce cytokines. J Allergy Clin Immun 108(3):430–438
129. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB
(2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical
findings. J Invest Dermatol 133(1):17–26
130. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK,
Schwarzenberger P, van de Loo FA, van den Berg WB (2001) IL-1-independent role of IL-17
in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol
167(2):1004–1013
131. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova
FE, Boots AM, Gram H, Joosten LA, van den Berg WB (2005) Blocking of interleukin-17
during reactivation of experimental arthritis prevents joint inflammation and bone erosion by
decreasing RANKL and interleukin-1. Am J Pathol 167(1):141–149
132. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R
(2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune
encephalomyelitis. Cell Immunol 237(2):123–130
133. Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, Ditto N, Lin Z, Yang X, Cotter
PZ, Shuster DJ, Song Y, Borowski V, Thomas RL, Heimrich EM, Devaux B, Das Gupta R,
Carvajal I, McIntyre KW, Xie J, Zhao Q, Struthers M, Salter-Cid LM (2015) Dual inhibition of
interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity.
J Pharmacol Exp Ther 354(2):152–165
134. Braun J, Baraliakos X, Kiltz U (2016) Secukinumab (AIN457) in the treatment of ankylosing
spondylitis. Expert Opin Biol Ther 16(5):711–722
135. Kurschus FC, Moos S (2017) IL-17 for therapy. J Dermatol Sci 87(3):221–227
136. Ishiguro A, Akiyama T, Adachi H, Inoue J, Nakamura Y (2011) Therapeutic potential of
anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of
autoimmunity in two mouse models. Arthritis Rheum 63(2):455–466
137. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman SJ, DunussiJoannopoulos K, Williams CMM, Wright JF, Fouser LA (2007) An IL-17F/A heterodimer
protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. Journal
of Immunology 179(11):7791–7799
138. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, Qiu Y, Whitters MJ, Tomkinson
KN, Dunussi-Joannopoulos K, Carreno BM, Collins M, Wolfman NM (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells. J Biol Chem
282(18):13447–13455
139. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus
RR, Zhu Z, Dong C (2008) Regulation of inflammatory responses by IL-17F. J Exp Med
205(5):1063–1075
171
124. Kirkham BW, Lassere MN, Edmonds JP, Juhasz KA, Bird PA, Lee CS, Shnier R, Portek IJ
(2006) Synovial membrane cytokine expression is predictive of joint damage progression in
rheumatoid arthritis - A two-year prospective study (the DAMAGE study cohort). Arthritis
Rheum 54(4):1122–1131
125. Graber JJ, Allie SR, Mullen KM, Jones MV, Wang T, Krishnan C, Kaplin AI, Nath A,
Kerr DA, Calabresi PA (2008) Interleukin-17 in transverse myelitis and multiple sclerosis. J
Neuroimmunol 196(1–2):124–132
126. Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham
C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang HY, Targan S, Datta LW, Kistner
EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH (2006)
A genome-wide association study identifies IL23R as an inflammatory bowel disease gene.
Science 314(5804):1461–1463
127. Emamaullee JA, Davis J, Merani S, Toso C, Elliott JF, Thiesen A, Shapiro AM (2009) Inhibition of Th17 cells regulates autoimmune diabetes in NOD mice. Diabetes 58(6):1302–1311
128. Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, Olivenstein R, Elias J, Chakir J
(2001) IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to
produce cytokines. J Allergy Clin Immun 108(3):430–438
129. Martin DA, Towne JE, Kricorian G, Klekotka P, Gudjonsson JE, Krueger JG, Russell CB
(2013) The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical
findings. J Invest Dermatol 133(1):17–26
130. Lubberts E, Joosten LA, Oppers B, van den Bersselaar L, Coenen-de Roo CJ, Kolls JK,
Schwarzenberger P, van de Loo FA, van den Berg WB (2001) IL-1-independent role of IL-17
in synovial inflammation and joint destruction during collagen-induced arthritis. J Immunol
167(2):1004–1013
131. Koenders MI, Lubberts E, Oppers-Walgreen B, van den Bersselaar L, Helsen MM, Di Padova
FE, Boots AM, Gram H, Joosten LA, van den Berg WB (2005) Blocking of interleukin-17
during reactivation of experimental arthritis prevents joint inflammation and bone erosion by
decreasing RANKL and interleukin-1. Am J Pathol 167(1):141–149
132. Hofstetter HH, Ibrahim SM, Koczan D, Kruse N, Weishaupt A, Toyka KV, Gold R
(2005) Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune
encephalomyelitis. Cell Immunol 237(2):123–130
133. Mangan PR, Su LJ, Jenny V, Tatum AL, Picarillo C, Skala S, Ditto N, Lin Z, Yang X, Cotter
PZ, Shuster DJ, Song Y, Borowski V, Thomas RL, Heimrich EM, Devaux B, Das Gupta R,
Carvajal I, McIntyre KW, Xie J, Zhao Q, Struthers M, Salter-Cid LM (2015) Dual inhibition of
interleukin-23 and interleukin-17 offers superior efficacy in mouse models of autoimmunity.
J Pharmacol Exp Ther 354(2):152–165
134. Braun J, Baraliakos X, Kiltz U (2016) Secukinumab (AIN457) in the treatment of ankylosing
spondylitis. Expert Opin Biol Ther 16(5):711–722
135. Kurschus FC, Moos S (2017) IL-17 for therapy. J Dermatol Sci 87(3):221–227
136. Ishiguro A, Akiyama T, Adachi H, Inoue J, Nakamura Y (2011) Therapeutic potential of
anti-interleukin-17A aptamer: suppression of interleukin-17A signaling and attenuation of
autoimmunity in two mouse models. Arthritis Rheum 63(2):455–466
137. Liang SC, Long AJ, Bennett F, Whitters MJ, Karim R, Collins M, Goldman SJ, DunussiJoannopoulos K, Williams CMM, Wright JF, Fouser LA (2007) An IL-17F/A heterodimer
protein is produced by mouse Th17 cells and induces airway neutrophil recruitment. Journal
of Immunology 179(11):7791–7799
138. Wright JF, Guo Y, Quazi A, Luxenberg DP, Bennett F, Ross JF, Qiu Y, Whitters MJ, Tomkinson
KN, Dunussi-Joannopoulos K, Carreno BM, Collins M, Wolfman NM (2007) Identification of an interleukin 17F/17A heterodimer in activated human CD4+T cells. J Biol Chem
282(18):13447–13455
139. Yang XO, Chang SH, Park H, Nurieva R, Shah B, Acero L, Wang YH, Schluns KS, Broaddus
RR, Zhu Z, Dong C (2008) Regulation of inflammatory responses by IL-17F. J Exp Med
205(5):1063–1075